Journal of Ecohumanism
2024
Volume: 3, No: 8, pp. 14167 – 14187
ISSN: 2752-6798 (Print) | ISSN 2752-6801 (Online)
https://ecohumanism.co.uk/joe/ecohumanism
DOI: https://doi.org/10.62754/joe.v3i8.6617

Thyrotoxicosis: An Updated Review for Physicians, Pharmacists, Anesthesiologists, and Healthcare Providers

Fahad Mohammed Al MEHMADI[1], husssein abdu hakami[2], Sheaya Ali Al-Otaibi[3], Afnan muteb dahesh quhal[4], ANAS FAHAD ALFEHAID[5], Abdullah Saad Hagshah[6], Khalid Mohammed Bin Mayuf[7], Salem Saud Alghamdi[8], shaqraa hsn Sufyani[9], Amal Abdulali Almutairi[10], JAMILA ABDULAALI ALMUTAIRI[11], Meshal meshari alotaibi[12], Munira Murshid Al-Harbi[13], Mohammed Mobarek Nasser Aldosari[14]

Abstract

Thyrotoxicosis is a clinical syndrome resulting from excessive thyroid hormone activity, primarily involving triiodothyronine (T3) and thyroxine (T4). It is distinct from hyperthyroidism, which specifically refers to overproduction of thyroid hormones by the thyroid gland. Thyrotoxicosis encompasses various conditions, including Graves' disease, thyroiditis, toxic nodules, and exogenous hormone intake. If untreated, it can lead to severe complications such as cardiovascular dysfunction, osteoporosis, and thyroid storm, a life-threatening emergency. The condition presents with diverse symptoms, including weight loss, heat intolerance, palpitations, and anxiety, necessitating a thorough diagnostic approach.This review aims to provide an updated overview of thyrotoxicosis, focusing on its etiology, pathophysiology, clinical presentation, diagnostic evaluation, and management strategies. It also highlights the importance of differentiating thyrotoxicosis from other conditions with similar presentations and discusses emerging therapies and ongoing research. Review also focusses on the main role of pharmacists and anesthesiologists in the management of thyrotoxicosis. The review synthesizes current literature on thyrotoxicosis, including its epidemiology, pathophysiology, and treatment modalities. It incorporates clinical guidelines, diagnostic criteria, and therapeutic approaches, supported by evidence from recent studies and trials. Special considerations for specific populations, such as pregnant women and children, are also discussed. Thyrotoxicosis is mostly caused by Graves' disease, toxic multinodular goiter, and thyroiditis. Diagnosis relies on suppressed TSH levels and elevated T3/T4 levels, with imaging studies aiding in identifying the underlying cause. Treatment options include beta-blockers for symptom relief, thionamide drugs, radioiodine therapy, and thyroidectomy. Emerging therapies, such as teprotumumab for Graves' orbitopathy, show promise. Early diagnosis and tailored treatment are crucial to prevent complications and improve outcomes.

Keywords: *Thyrotoxicosis, Hyperthyroidism, Graves' Disease, Thyroiditis, Radioiodine Therapy, Thyroid Storm, Teprotumumab.*

Introduction

Thyrotoxicosis is a clinical syndrome resulting from excessive thyroid hormone activity in the body, primarily involving triiodothyronine (T3) and thyroxine (T4). It is important to distinguish thyrotoxicosis

[1] Ksa, Ministry of Health, Hospital lmam Abdul Rahman Al-Faisal in Riyady
[2] Ksa, Ministry of Health, Asir Central Hospital.
[3] Ksa, Ministry of Health, Muzahimiyah General Hospital.
[4] Ksa, Ministry of Health, Al-Harith General Hospital.
[5] Ksa, Ministry of Health, AlAsyah General Hospital
[6] Ksa, Ministry of Health, Riyadh First Health Cluster
[7] Ksa, Ministry of Health, Riyadh First Health Cluster
[8] Ksa, Ministry of Health, Riyadh First Health Cluster
[9] Ksa, Ministry of Health, al ardah hospital
[10] Ksa, Ministry of Health, Al Yamamah Hospital
[11] Ksa, Ministry of Health, Alyamamah hospital
[12] Ksa,Ministry of Health, King Abdulaziz Hospital
[13] Ksa, Ministry of Health, Al Yamamah Hospital
[14] Ksa, Ministry of Health, Wadi Aldawaser Hospital

Journal of Ecohumanism
2024
Volume: 3, No: 8, pp. 14167 – 14187
ISSN: 2752-6798 (Print) | ISSN 2752-6801 (Online)
https://ecohumanism.co.uk/joe/ecohumanism
DOI: https://doi.org/10.62754/joe.v3i8.6617

from hyperthyroidism, as the latter is a subset of thyrotoxicosis specifically caused by overproduction of thyroid hormones by the thyroid gland. Thyrotoxicosis, however, encompasses all conditions characterized by elevated thyroid hormone levels, regardless of the source. These conditions include Graves' disease, thyroiditis, toxic nodules, multinodular goiter, and exogenous hormone intake, among others. If left untreated, thyrotoxicosis can lead to severe complications such as cardiovascular issues, osteoporosis, and thyroid storm—a critical, life-threatening condition requiring immediate medical intervention.[1][2] The clinical manifestations of thyrotoxicosis are diverse and stem from the hypermetabolic state induced by excess thyroid hormones. Common symptoms include unexplained weight loss despite normal or increased appetite, heat intolerance, excessive sweating, palpitations, tremors, anxiety, and fatigue. Patients may also experience gastrointestinal disturbances, menstrual irregularities, and muscle weakness. In severe cases, particularly during a thyroid storm, symptoms can escalate to include fever, tachycardia, confusion, and even coma. Given the wide range of presentations, a thorough medical history, physical examination, and diagnostic testing are crucial for accurate diagnosis and management. Laboratory tests typically reveal suppressed thyroid-stimulating hormone (TSH) levels and elevated T3 and T4 levels, while imaging studies such as thyroid ultrasound or radioactive iodine uptake scans help identify the underlying cause.[2]

The thyroid gland, a butterfly-shaped organ located in the anterior neck, plays a central role in regulating metabolism through the production and release of T3 and T4. These hormones influence nearly every tissue in the body, affecting processes such as energy expenditure, heart rate, and temperature regulation. The release of thyroid hormones is controlled by TSH, which is secreted by the anterior pituitary gland. In thyrotoxicosis, this regulatory mechanism is disrupted, leading to excessive circulating levels of thyroid hormones and a consequent hypermetabolic state.[3] Treatment strategies vary depending on the cause and severity of the condition and may include antithyroid medications, radioactive iodine therapy, or surgical intervention. Early diagnosis and appropriate management are essential to prevent complications and improve patient outcomes. The natural history of thyrotoxicosis is highly variable and depends on the underlying etiology. In hyperthyroid conditions such as Graves' disease, the overproduction of thyroid hormones tends to persist and may worsen over time if left untreated. Graves' disease, an autoimmune disorder, is characterized by the production of thyroid-stimulating immunoglobulins that continuously activate the thyroid gland, leading to sustained thyrotoxicosis. In contrast, conditions like thyroiditis often follow a self-limiting course. For example, subacute thyroiditis typically involves an initial phase of thyrotoxicosis due to the release of preformed hormones from inflamed thyroid tissue, followed by a hypothyroid phase, and eventual recovery as the inflammation resolves. However, even in self-limiting cases, untreated thyrotoxicosis can result in significant systemic complications, including neuropsychiatric manifestations such as anxiety, irritability, and cognitive impairment.[3]

The systemic effects of thyrotoxicosis are profound due to the widespread influence of thyroid hormones on multiple organ systems. The cardiovascular system is particularly vulnerable, with complications such as tachycardia, atrial fibrillation, heart failure, thromboembolic events, and, in severe cases, cardiovascular collapse.[2][4] Excess thyroid hormones also disrupt bone metabolism, accelerating bone resorption and increasing the risk of osteoporosis and fractures. Neurological manifestations range from tremors and anxiety to severe delirium, especially during a thyroid storm—a life-threatening exacerbation of thyrotoxicosis.[5] Recent studies have further highlighted the association between thyrotoxicosis and cognitive disorders, particularly in older adults aged 65 and above, emphasizing the importance of timely diagnosis and management.[6] Addressing the underlying cause of thyrotoxicosis is critical to mitigating its systemic effects and preventing long-term complications. Early intervention can significantly improve outcomes and reduce the risk of severe morbidity.

Etiology of Thyrotoxicosis

The etiology of thyrotoxicosis can be broadly categorized into endogenous and exogenous sources of thyroid hormones. Endogenous causes involve the overproduction or release of thyroid hormones from the thyroid gland or other tissues, while exogenous causes result from the external intake of thyroid hormones or substances that stimulate thyroid hormone production. Understanding the underlying cause is critical for accurate diagnosis and effective management.

Journal of Ecohumanism
2024
Volume: 3, No: 8, pp. 14167 – 14187
ISSN: 2752-6798 (Print) | ISSN 2752-6801 (Online)
https://ecohumanism.co.uk/joe/ecohumanism
DOI: https://doi.org/10.62754/joe.v3i8.6617

Increased Endogenous Secretion of Thyroid Hormone

Graves Disease: Graves disease is the most common cause of hyperthyroidism and thyrotoxicosis in the United States, accounting for 60% to 80% of cases. It is an autoimmune disorder characterized by the production of thyroid-stimulating immunoglobulins (TSIs) that bind to and activate the thyroid-stimulating hormone (TSH) receptor. This continuous stimulation leads to excessive thyroid hormone production and hyperplasia of thyroid follicular cells, resulting in a diffuse goiter. The exact cause of Graves' disease remains unclear, but it is believed to involve a combination of genetic predisposition and environmental triggers, such as smoking, stress, and dietary iodine. Graves' disease is also associated with other autoimmune conditions, including type 1 diabetes and vitiligo. For more detailed information, refer to StatPearls' companion resource, "Graves Disease."[7][8][9]

Toxic Multinodular Goiter: Toxic multinodular Goiter (TMNG) is the second most common cause of thyrotoxicosis, particularly in older adults and regions with iodine deficiency. TMNG is characterized by the presence of multiple autonomously functioning thyroid nodules that produce excessive thyroid hormones independent of TSH regulation. These nodules develop over time due to chronic stimulation of the thyroid gland, often in response to iodine deficiency or other growth factors. In rare cases, nontoxic adenomas or goiters may convert to toxic adenomas after exposure to iodinated contrast, a phenomenon known as the Jod-Basedow effect. For further details, consult StatPearls' companion resource, "Toxic Multinodular Goiter."[10][11][12]

Toxic Adenoma: A toxic adenoma, also referred to as a hyperfunctioning adenoma or follicular adenoma, is a single autonomously functioning nodule within the thyroid gland that secretes excessive thyroid hormone. These nodules are benign, encapsulated, and noninvasive, demonstrating thyroid follicular cell differentiation without the nuclear features of papillary thyroid cancer. Although typically benign, toxic adenomas can lead to clinical thyrotoxicosis, especially in iodine-deficient regions.[4][13]

Thyroid-Stimulating Hormone–Producing Adenoma (Pituitary Adenoma): TSH-producing adenomas are rare causes of thyrotoxicosis, accounting for less than 1% of all pituitary adenomas. Unlike most forms of hyperthyroidism, where TSH levels are suppressed, patients with TSH-producing adenomas present with inappropriately normal or elevated TSH levels alongside high T3 and T4 levels. These adenomas are often detected incidentally and require careful evaluation to differentiate them from other causes of thyrotoxicosis.[14][15]

Human Chorionic Gonadotropin–Mediated Hyperthyroidism: Human chorionic gonadotropin (hCG)–mediated hyperthyroidism occurs when hCG, which is structurally like TSH, stimulates the TSH receptor. This condition is most observed during the first trimester of pregnancy or because of infertility treatments. In conditions such as gestational trophoblastic disease or choriocarcinoma, excessive hCG production can lead to hyperthyroidism. This form of thyrotoxicosis is typically transient and resolved after the underlying cause is addressed.[2][16]

Thyroiditis: Thyroiditis encompasses several conditions that cause inflammation of the thyroid gland, leading to the release of preformed thyroid hormones and transient thyrotoxicosis. Common forms include:

- Subacute (De Quervain) thyroiditis: Often triggered by viral infections, this condition is characterized by painful thyroid inflammation and transient thyrotoxicosis followed by a hypothyroid phase.

- Painless thyroiditis: This form is often associated with autoimmune thyroid disease and is characterized by painless thyroid inflammation and transient thyrotoxicosis.

- Postpartum thyroiditis: Occurring within the first year after childbirth, this condition involves transient thyrotoxicosis followed by hypothyroidism.

Journal of Ecohumanism
2024
Volume: 3, No: 8, pp. 14167 – 14187
ISSN: 2752-6798 (Print) | ISSN 2752-6801 (Online)
https://ecohumanism.co.uk/joe/ecohumanism
DOI: https://doi.org/10.62754/joe.v3i8.6617

- Reidel thyroiditis: A rare condition characterized by progressive fibrosis of the thyroid gland, often associated with IgG4-related sclerosing disease.

In most cases of thyroiditis, thyroid function eventually normalizes after the inflammatory phase resolves. For more information, refer to StatPearls' companion resource, "Thyroiditis."[4]

Drug-Induced Thyrotoxicosis

Certain medications can induce thyrotoxicosis through various mechanisms:

- Amiodarone: This iodine-rich antiarrhythmic drug can cause both type 1 (increased hormone synthesis in predisposed individuals) and type 2 (destructive thyroiditis) thyrotoxicosis.

- Iodinated contrast agents: These agents can lead to thyrotoxicosis, typically 2 to 12 weeks after exposure, through the Jod-Basedow effect.

- Immune checkpoint inhibitors: These newer medications, used in cancer therapy, can cause thyrotoxicosis through hyperthyroidism or thyroiditis. The incidence is as high as 8% with combined PD-1 and anti-CTLA-4 treatment. Thyrotoxicosis typically occurs within 1 to 2 months of initiating therapy but can be presented as late as 12 months after treatment begins. For further details, consult StatPearls' companion resource, "Endocrine-Related Adverse Events from Immune Checkpoint Inhibitors."[17]

Increased Exogenous Secretion of Thyroid Hormone

Factitious Hyperthyroidism: Factitious hyperthyroidism occurs when individuals intentionally ingest thyroid hormone medications without medical supervision, often with the goal of weight loss. This behavior is observed in various populations, including competitive athletes and individuals with psychiatric disorders such as Munchausen syndrome. Diagnosis requires a high index of suspicion and careful evaluation of medication history.[21][22]

Excessive Levothyroxine Replacement Therapy (Iatrogenic): Iatrogenic thyrotoxicosis can result from excessive levothyroxine replacement therapy, often due to improper dosing or lack of monitoring. This condition is particularly common in patients with hypothyroidism who are overtreated with thyroid hormone replacement.

Rare Causes of Thyrotoxicosis

Struma Ovarii: Struma ovarii is a rare form of ovarian teratoma that contains functional thyroid tissue capable of producing thyroid hormones. This condition can lead to thyrotoxicosis, particularly if the thyroid tissue becomes hyperactive.[19]

Gestational Trophoblastic Neoplasia: Gestational trophoblastic neoplasia, including conditions such as hydatidiform mole and choriocarcinoma, can cause thyrotoxicosis due to excessive hCG production, which stimulates the TSH receptor.[16]

Activating Mutations of the TSH Receptor: Activating mutations in the TSH receptor gene can lead to autonomous thyroid hormone production, resulting in thyrotoxicosis. These mutations are rare but should be considered in cases of unexplained hyperthyroidism.

Functional Thyroid Cancer Metastases: In rare cases, metastatic thyroid cancer can produce excessive thyroid hormones, leading to thyrotoxicosis. This is more commonly observed in follicular thyroid carcinoma.

Journal of Ecohumanism
2024
Volume: 3, No: 8, pp. 14167 – 14187
ISSN: 2752-6798 (Print) | ISSN 2752-6801 (Online)
https://ecohumanism.co.uk/joe/ecohumanism
DOI: https://doi.org/10.62754/joe.v3i8.6617

Hamburger Thyrotoxicosis: Hamburger thyrotoxicosis is a rare condition caused by the contamination of ground meat with thyroid tissue from animals. This condition should be suspected in the context of community outbreaks or when meat is prepared by inexperienced butchers.[20] The etiology of thyrotoxicosis is diverse, encompassing a wide range of endogenous and exogenous causes. Graves disease is the most common cause, followed by toxic multinodular goiter and toxic adenoma. Rare causes, such as TSH-producing adenomas, struma ovarii, and factitious hyperthyroidism, require careful evaluation and a high index of suspicion. Understanding the underlying cause is essential for guiding appropriate treatment and preventing complications. Early diagnosis and management are critical to improving patient outcomes and reducing the risk of long-term sequelae.

Epidemiology of Thyrotoxicosis

The global prevalence of hyperthyroidism, a common cause of thyrotoxicosis, is estimated to range between 0.2% and 1.2%, while subclinical hyperthyroidism, characterized by suppressed thyroid-stimulating hormone (TSH) levels with normal triiodothyronine (T3) and thyroxine (T4) levels, affects approximately 0.7% to 1.4% of the population.[4] The incidence of thyrotoxicosis is highest among individuals aged 20 to 50 years, with recent studies highlighting a higher prevalence of subclinical thyrotoxicosis in older populations. This increased prevalence, particularly in individuals aged 65 or older, is attributed to more frequent screening, with rates rising from 2% to 3% in this age group. Women are disproportionately affected by thyrotoxicosis, with a female-to-male ratio of 7:1 to 10:1, reflecting the influence of hormonal and autoimmune factors in the disease's pathogenesis.[8] Graves' disease is the leading cause of thyrotoxicosis in iodine-replete countries, with an incidence of 20 to 50 cases per 100,000 individuals. This autoimmune disorder most commonly affects women aged 30 to 50 years, with a male-to-female ratio of 1:5, although it can occur at any age and in both genders. Following Graves' disease, toxic multinodular goiter is the second most common cause of thyrotoxicosis, with an incidence of 1.5 to 18 cases per 100,000 individuals. Toxic multinodular goiter is more prevalent in older adults and in regions with iodine deficiency, where chronic stimulation of the thyroid gland leads to the development of autonomously functioning nodules.[14][23] Thyroiditis, which includes conditions such as subacute thyroiditis, painless thyroiditis, and postpartum thyroiditis, accounts for approximately 10% of thyrotoxicosis cases. These conditions often present with transient thyrotoxicosis followed by a hypothyroid phase, with eventual normalization of thyroid function in most cases. Although the incidence of thyroid storm, a life-threatening complication of thyrotoxicosis, remains low at less than 2%, recent studies emphasize the importance of early detection and treatment due to its high mortality rate, which can exceed 10% to 20% if not promptly managed.[2][24] Globally, iodine intake plays a significant role in the epidemiology of thyrotoxicosis. In iodine-sufficient regions, Graves' disease is the predominant cause of thyrotoxicosis, while toxic multinodular goiter and toxic adenoma are more common in iodine-deficient areas. This disparity underscores the importance of adequate iodine intake in preventing thyroid disorders, particularly in regions where dietary iodine is insufficient.[25] Understanding the epidemiology of thyrotoxicosis is essential for developing targeted screening and prevention strategies, particularly in high-risk populations such as older adults and women. Early diagnosis and management are critical to reducing the burden of disease and preventing severe complications, including thyroid storm and long-term cardiovascular and skeletal sequelae.

Pathophysiology of Thyrotoxicosis

Thyrotoxicosis is a hypermetabolic state resulting from excessive circulating levels of thyroid hormones, primarily triiodothyronine (T3) and thyroxine (T4). These hormones exert widespread effects on nearly every tissue and organ system, primarily by increasing the basal metabolic rate and enhancing tissue thermogenesis. This is achieved through the upregulation of β-adrenergic receptors, which amplifies sympathetic nervous system activity. The clinical manifestations of thyrotoxicosis can range from asymptomatic to life-threatening conditions such as thyroid storm, depending on the severity and duration of hormone excess.[26]

Journal of Ecohumanism
2024
Volume: 3, No: 8, pp. 14167 – 14187
ISSN: 2752-6798 (Print) | ISSN 2752-6801 (Online)
https://ecohumanism.co.uk/joe/ecohumanism
DOI: https://doi.org/10.62754/joe.v3i8.6617

Cardiovascular System

The cardiovascular system is particularly sensitive to the effects of thyroid hormones. T3 and T4 increase both inotropy (contractility) and chronotropy (heart rate) by enhancing the expression of myocardial sarcoplasmic reticulum calcium-dependent ATPase. This leads to increased calcium reuptake and release, resulting in greater myocardial contractility and a higher heart rate. These changes collectively elevate cardiac output, which is a hallmark of thyrotoxicosis.[27] Additionally, thyroid hormones cause arterial smooth muscle relaxation, mediated by metabolic byproducts such as lactic acid generated during increased oxygen consumption. This relaxation reduces systemic vascular resistance (SVR) and afterload, further contributing to increased cardiac output. The reduction in SVR activates the renin-angiotensin-aldosterone system (RAAS), promoting sodium reabsorption and blood volume expansion, which increases preload. Over time, these hemodynamic changes can lead to left ventricular hypertrophy and, if untreated, congestive heart failure.[28][29]

Central Nervous System

Thyroid hormones play a critical role in the development and function of the central nervous system (CNS). From embryonic stages through adulthood, these hormones regulate processes such as neuronal proliferation, differentiation, migration, synaptogenesis, and myelination. They are also essential for the development of visual and auditory structures and the cerebellar regulation of gait. In adults, thyrotoxicosis can lead to neuropsychiatric symptoms, including anxiety, irritability, and cognitive impairment, which may be linked to hypermetabolism or increased sympathetic activity.[30]

Metabolism

The thyroid gland is a key regulator of metabolism. In thyrotoxicosis, the basal metabolic rate can increase by up to 50%, leading to symptoms such as weight loss and heat intolerance. This hypermetabolic state is partially mediated through the sympathetic nervous system, which is overactivated in response to excess thyroid hormones. Additionally, thyrotropin-releasing hormone (TRH) production is influenced by caloric intake, with reduced intake potentially leading to central hypothyroidism. This interplay highlights the thyroid's role in maintaining metabolic homeostasis.[30][31]

Skeletal Muscle

Thyroid hormones are essential for the differentiation and functional regulation of skeletal muscle. They influence glucose uptake, fiber type changes, and the activity of satellite cells, which are critical for muscle repair and growth. In thyrotoxicosis, proximal muscle weakness is a common clinical finding, often attributed to the catabolic effects of excess thyroid hormones on muscle tissue. The enzymes type-2 (DIO2) and type-3 (DIO3) iodothyronine deiodinases play a key role in mediating these effects by regulating the local availability of active thyroid hormones in muscle tissue.[32][33]

Bone Metabolism

Thyroid hormones have profound effects on bone metabolism. Thyroid-stimulating hormone (TSH) regulates bone development, and low or low-normal TSH levels are associated with decreased bone mass, increased osteoporosis, and a higher risk of fractures. These effects appear to be independent of thyroid hormone levels, suggesting a direct role for TSH in bone homeostasis. Additionally, T3 and T4 activate the bone morphogenetic protein (BMP) pathway, enhancing osteoblast activity and promoting bone resorption. In children, thyrotoxicosis can lead to premature closure of growth plates and skull sutures, resulting in short stature and craniosynostosis. These changes are mediated through interactions between thyroid hormones and signaling pathways such as insulin-like growth factor-1 (IGF1), fibroblast growth factor (FGF), Indian hedgehog (IHH), and Wnt.[34][35][36]

Journal of Ecohumanism
2024
Volume: 3, No: 8, pp. 14167 – 14187
ISSN: 2752-6798 (Print) | ISSN 2752-6801 (Online)
https://ecohumanism.co.uk/joe/ecohumanism
DOI: https://doi.org/10.62754/joe.v3i8.6617

Psychiatric Manifestations

Thyrotoxicosis can have significant psychiatric effects, particularly in older adults. Studies have shown that individuals aged 65 or older with low TSH levels, whether due to endogenous or exogenous causes, have higher rates of dementia and mild cognitive impairment. This is concerning given the widespread use of thyroid hormone replacement therapy in this population. Other psychiatric symptoms associated with thyrotoxicosis include anxiety, insomnia, paranoia, and, in severe cases, psychosis. While the exact mechanisms remain unclear, these symptoms may be linked to the hypermetabolic state or increased sympathetic nervous system activity.[6][37][38]

Thyroid Eye Disease

The association between the eyes and hyperthyroidism has been recognized for centuries, yet the pathophysiology of thyroid eye disease (TED) remains incompletely understood. TED is believed to involve a complex immune-mediated process that includes orbital fibroblasts, adipocytes, and lymphocytes. These cells interact in a cycle of inflammation and tissue remodeling, leading to the characteristic features of TED, such as proptosis, periorbital edema, and diplopia. For more detailed information, refer to StatPearls' companion resource, "Thyroid Eye Disease." The pathophysiology of thyrotoxicosis involves a complex interplay of hormonal, metabolic, and systemic effects. Thyroid hormones exert widespread actions on the cardiovascular, nervous, musculoskeletal, and metabolic systems, leading to the diverse clinical manifestations of the condition. Understanding these mechanisms is essential for accurate diagnosis and effective management. Early intervention can mitigate the risk of severe complications, including cardiovascular dysfunction, osteoporosis, and neuropsychiatric disorders, thereby improving patient outcomes.

Histopathology of Thyrotoxicosis

The histopathological features of thyrotoxicosis vary depending on the underlying cause, with distinct patterns observed in conditions such as toxic multinodular goiter, toxic adenoma, Graves' disease, and thyroiditis. These histological findings are critical for accurate diagnosis and differentiation between benign and malignant thyroid disorders.

Toxic Multinodular Goiter and Toxic Adenoma

Toxic multinodular goiter and toxic adenoma are types of follicular adenomas, which are characterized by a non-malignant proliferation of thyroid follicles enclosed within a fibrous capsule. These adenomas are typically benign and nonfunctional, meaning they do not secrete thyroid hormones under normal circumstances. However, in toxic adenomas, the follicular cells become autonomously functional, leading to excessive thyroid hormone production. Histologically, these nodules are well-defined and composed of uniform follicular cells with minimal atypia. The surrounding thyroid tissue may show compensatory changes, such as follicular hyperplasia, due to the suppression of thyroid-stimulating hormone (TSH) by the autonomously functioning nodule.[2]

Follicular Hyperplasia

In thyrotoxicosis, particularly in Graves' disease, histological examination often reveals follicular hyperplasia. This condition is characterized by an increase in the number of follicular cells and a reduction in colloid within the follicles, reflecting heightened thyroid hormone synthesis. The follicular cells may appear tall and columnar, with the scalloping of the colloid at the edges of the follicles. Differentiating benign follicular hyperplasia from papillary thyroid carcinoma can be challenging, as some cases of hyperplasia may exhibit papillary structures and nuclear features resembling malignancy. Key histopathological features to consider include nuclear enlargement, cellular atypia, increased mitotic activity, pseudonuclear inclusions, Psammoma bodies, and nuclear pleomorphism.[39]

Journal of Ecohumanism
2024
Volume: 3, No: 8, pp. 14167 – 14187
ISSN: 2752-6798 (Print) | ISSN 2752-6801 (Online)
https://ecohumanism.co.uk/joe/ecohumanism
DOI: https://doi.org/10.62754/joe.v3i8.6617

Graves' Disease

Graves' disease is associated with both lymphocytic infiltration and follicular hyperplasia. The lymphocytic infiltration is driven by autoimmune processes, with the presence of thyroglobulin antibodies and myeloperoxidase antibodies indicating immune-mediated destruction of thyroid tissue. Additionally, thyroid receptor antibodies (TRAb) stimulate the TSH receptor, leading to follicular hyperplasia and excessive hormone production. Studies have shown that the degree of lymphocytic infiltration correlates with the severity of symptoms and the likelihood of remission following treatment. Histologically, the thyroid gland in Graves' disease appears diffusely enlarged, with hyperplastic follicles and scattered lymphocytes.[40]

Thyroiditis

In cases of thyroiditis leading to thyrotoxicosis, such as subacute thyroiditis, histopathological examination typically reveals destruction of thyroid follicles accompanied by lymphocytic infiltration. This follicular destruction results in the release of preformed thyroid hormones, causing transient thyrotoxicosis. The presence of thyroglobulin antibodies and myeloperoxidase antibodies further supports an immune-mediated mechanism. Unlike Graves' disease, thyroiditis is characterized by a destructive process rather than follicular hyperplasia, distinguishing it from other causes of thyrotoxicosis.[40] The histopathological features of thyrotoxicosis provide valuable insights into the underlying etiology and pathogenesis of the condition. Follicular hyperplasia is a common finding in Graves' disease, while follicular destruction and lymphocytic infiltration are hallmark features of thyroiditis. Accurate histological diagnosis is essential for differentiating benign conditions from malignant thyroid disorders and guiding appropriate treatment strategies. Understanding these histopathological patterns enhances the ability to manage thyrotoxicosis effectively and improve patient outcomes.

Toxicokinetics of Thyrotoxicosis

Toxicokinetics refers to the study of how thyroid hormones are absorbed, distributed, metabolized, and eliminated in the body. Understanding these processes is essential for managing thyrotoxicosis, as they influence the onset, duration, and severity of symptoms. Thyroid hormones, primarily thyroxine (T4) and triiodothyronine (T3), are absorbed through the gastrointestinal tract. The bioavailability of these hormones can be influenced by several factors, including dietary components, the presence of medications (such as calcium or iron supplements), and the formulation of thyroid hormone replacements like levothyroxine. For example, levothyroxine absorption is optimal when taken on an empty stomach, as food and certain medications can interfere with its uptake.[16] Once absorbed, thyroid hormones circulate in the bloodstream, predominantly bound to plasma proteins such as thyroxine-binding globulin (TBG), albumin, and transthyretin. Only the unbound (free) fraction of these hormones is biologically active and capable of entering cells to exert metabolic effects. The balance between bound and free hormones is crucial for maintaining thyroid hormone activity and preventing toxicity. Thyroid hormones are primarily metabolized in the liver and other tissues. A key metabolic process is the conversion of T4 to T3, the more biologically active form of thyroid hormone. This conversion is mediated by enzymes such as deiodinases and is critical for regulating the physiological effects of thyroid hormones. Factors such as liver function, genetic polymorphisms in deiodinase enzymes, and the presence of certain medications can influence this metabolic process, altering hormone activity and contributing to thyrotoxicosis. Thyroid hormones are eliminated primarily through the kidneys. The half-life of T4 is approximately 7 days, while T3 has a shorter half-life of about 1 day. This difference in half-life is important when assessing the duration of action and potential for toxicity. For instance, excessive T4 intake may lead to prolonged thyrotoxicosis due to its longer half-life, whereas T3 toxicity may be resolved more quickly. The toxicokinetic of thyroid hormones—absorption, distribution, metabolism, and elimination—play a critical role in the development and management of thyrotoxicosis. Factors such as dietary intake, liver function, and genetic variations can significantly influence these processes, affecting hormone levels and clinical outcomes. Understanding these mechanisms is essential for optimizing treatment strategies and minimizing the risk of toxicity in patients with thyrotoxicosis.

History and Physical Examination in Thyrotoxicosis

Journal of Ecohumanism
2024
Volume: 3, No: 8, pp. 14167 – 14187
ISSN: 2752-6798 (Print) | ISSN 2752-6801 (Online)
https://ecohumanism.co.uk/joe/ecohumanism
DOI: https://doi.org/10.62754/joe.v3i8.6617

Patients with thyrotoxicosis typically present with a wide range of signs and symptoms resulting from the systemic effects of excess thyroid hormones. These manifestations can affect multiple organ systems, and their severity often correlates with the degree of hormone excess. A thorough history and physical examination are essential for identifying the underlying cause and guiding appropriate management.

Cardiovascular Manifestations

The cardiovascular system is highly sensitive to the effects of thyroid hormones, and patients often present with symptoms such as palpitations, tachycardia, atrial fibrillation, dyspnea, orthopnea, and edema (in cases of congestive heart failure).[5] Sinus tachycardia is the most common cardiac rhythm disturbance in thyrotoxicosis, but atrial fibrillation is also prevalent, particularly in older adults or those with preexisting conditions such as valvular disease or coronary artery disease. In older individuals, cardiovascular symptoms may dominate clinical presentation, often overshadowing other typical signs of thyrotoxicosis. This phenomenon, known as "apathetic hyperthyroidism," is characterized by symptoms such as heart failure, arrhythmias, hypercalcemia, depression, fatigue, and weight loss, which can be mistaken for age-related conditions.[8]

Neurological Manifestations

Thyroid hormones play a critical role in the nervous system, and their excess can lead to neurological symptoms such as proximal muscle weakness, brisk deep tendon reflexes with a rapid relaxation phase, and tremors.[11] These symptoms result from the hypermetabolic state and increased sympathetic nervous system activity associated with thyrotoxicosis.

Gastrointestinal and Metabolic Manifestations

The metabolic effects of thyroid hormones often lead to weight loss despite an increased appetite, as well as diarrhea and hyperdefecation.[41] These symptoms reflect the heightened metabolic rate and increased gastrointestinal motility caused by excess thyroid hormones.

Psychiatric Manifestations

Thyrotoxicosis can significantly impact mental health, leading to symptoms such as anxiety, insomnia, cognitive impairment, and, in severe cases, psychosis.[6][37][38] These manifestations are thought to result from the hypermetabolic state and increased adrenergic activity, which can disrupt normal brain function.

Adrenergic Stimulation

Excess thyroid hormones amplify the effects of the sympathetic nervous system, leading to symptoms such as heat intolerance, hyperthermia, and increased sweating.[11] These adrenergic symptoms are common in thyrotoxicosis and often contribute to the patient's overall discomfort.

Dermatological Manifestations

Thyrotoxicosis can cause a variety of skin changes, including onycholysis (separation of the nail from the nail bed), vitiligo, pretibial myxedema, and thyroid acropachy (clubbing of the fingers and toes with swelling of the hands and feet).[42][43] These dermatological findings are often associated with autoimmune thyroid diseases such as Graves' disease.

Ocular Manifestations

Journal of Ecohumanism
2024
Volume: 3, No: 8, pp. 14167 – 14187
ISSN: 2752-6798 (Print) | ISSN 2752-6801 (Online)
https://ecohumanism.co.uk/joe/ecohumanism
DOI: https://doi.org/10.62754/joe.v3i8.6617

Ocular symptoms are a hallmark of Graves' disease and may include exophthalmos, increased lacrimation, blurry vision, diplopia, photophobia, decreased color vision, and periorbital edema.[11] These symptoms result from the immune-mediated inflammation of orbital tissues, which is characteristic of Graves' orbitopathy. For more detailed information, refer to StatPearls' companion resource, "Thyroid Eye Disease."

Reproductive Manifestations

Thyrotoxicosis can disrupt normal reproductive function, leading to symptoms such as amenorrhea, oligomenorrhea, and gynecomastia.[15] These changes are thought to result from the effects of excess thyroid hormones on the hypothalamic-pituitary-gonadal axis.

Compressive Symptoms

In cases where the thyroid gland becomes significantly enlarged, patients may experience compressive symptoms such as hoarseness, dysphagia, and orthopnea.[4][11] These symptoms result from the physical compression of adjacent structures by the enlarged thyroid.

Physical Examination Findings: On physical examination, patients with thyrotoxicosis often appear cachectic, hyperthermic, diaphoretic, and anxious. Common findings include:

- Goiter: An enlarged thyroid gland, which may be diffuse or nodular.
- Palpable nodules: Suggestive of toxic multinodular goiter or toxic adenoma.
- Tachycardia or atrial fibrillation: Reflecting the cardiovascular effects of excess thyroid hormones.
- Systolic hypertension: Resulting from increased cardiac output and reduced systemic vascular resistance.
- Dyspnea: Often due to high-output heart failure or respiratory muscle weakness.
- Abdominal tenderness: Possibly related to increased gastrointestinal motility.
- Hyperreflexia: A neurological sign of increased adrenergic activity.
- Proximal muscle weakness: A hallmark of thyrotoxic myopathy.
- Tremor: A fine, rapid tremor often observed in the hands.
- Gynecomastia: Resulting from hormonal imbalances.
- Short stature in affected children: Due to premature closure of growth plates.
- Stare and lid lag: Ocular signs associated with Graves' disease.[2][4][11][44]

Thyroid Storm

In rare cases, patients may present with thyroid storm, a life-threatening exacerbation of thyrotoxicosis characterized by tachycardia, fever, altered mental status, agitation, signs of cardiac failure, and impaired liver function. Hyperthermia, with body temperatures ranging between 104 °F and 106 °F (40 °C to 41 °C), is a key finding. Thyroid storm carries a mortality rate of up to 25%, making urgent recognition and treatment critical. For more information, refer to StatPearls' companion resource, "Thyroid Storm."

Journal of Ecohumanism
2024
Volume: 3, No: 8, pp. 14167 – 14187
ISSN: 2752-6798 (Print) | ISSN 2752-6801 (Online)
https://ecohumanism.co.uk/joe/ecohumanism
DOI: https://doi.org/10.62754/joe.v3i8.6617

Graves' Disease-Specific Findings

Patients with Graves' disease may exhibit additional findings such as ophthalmopathy (proptosis, chemosis, conjunctival injection, lid lag, exposure keratitis, and extraocular muscle dysfunction), pretibial myxedema, and thyroid acropachy. Clinically significant Graves orbitopathy occurs in 25% of patients with Graves' disease, while thyroid dermopathy, a rare condition affecting 1% to 4% of individuals, is almost always associated with Graves orbitopathy.[44]

Thyroiditis

In subacute thyroiditis, patients may report a recent upper respiratory illness and typically present with fever, neck pain, and swelling, along with a firm and tender thyroid gland. Painless thyroiditis often occurs in the postpartum period and is associated with a personal or family history of autoimmune or thyroid disorders. Suppurative thyroiditis presents with a tender, erythematous mass in the anterior neck, accompanied by fever, dysphagia, and dysphonia. Drug-induced thyroiditis may be associated with medications such as amiodarone, lithium, iodinated contrast, or immune checkpoint inhibitors.[44]

Neonatal Thyrotoxicosis

Neonatal thyrotoxicosis, caused by maternal autoimmune hyperthyroidism, may present with tachycardia, irritability with tremors, poor feeding, sweating, difficulty sleeping, emaciation, proptosis, and goiter. Severe cases can lead to craniosynostosis and microcephaly. Rare signs, such as thrombocytopenia, may mimic infection or sepsis.[45]

Rare Presentations

In rare cases, patients may present with thyrotoxic periodic paralysis, characterized by acute muscle paralysis and severe hypokalemia. In the case of a TSH-secreting pituitary adenoma, a visual field defect may also be present.[11] The history and physical examination are critical components of the diagnostic process in thyrotoxicosis. Recognizing the diverse clinical manifestations of this condition is essential for accurate diagnosis and timely intervention. Early identification of severe complications, such as thyroid storm, can significantly improve patient outcomes and reduce mortality.

Evaluation of Thyrotoxicosis

The evaluation of thyrotoxicosis involves a combination of clinical assessment, laboratory testing, and imaging studies to confirm the diagnosis, identify the underlying cause, and guide appropriate treatment. A systematic approach is essential to differentiate between the various etiologies of thyrotoxicosis and to assess the severity of the condition.

Laboratory Testing

The cornerstone of diagnosing thyrotoxicosis is the measurement of thyroid-stimulating hormone (TSH) and thyroid hormone levels. A low serum TSH level (<0.01 mU/L) demonstrates high sensitivity and specificity for thyroid disorders, as TSH is suppressed in response to elevated thyroid hormone levels. When TSH is low, elevated serum free T4 (fT4) and T3 levels can differentiate between overt hyperthyroidism and subclinical hyperthyroidism. In overt hyperthyroidism, both fT4 and T3 are elevated, whereas in subclinical hyperthyroidism, only TSH is suppressed, with thyroid hormone levels remaining within the normal range. Notably, T3 levels often rise before T4 levels in early thyrotoxicosis, making T3 a more sensitive marker in some cases. Variations in a patient's baseline TSH and T4 levels may correlate more closely with clinical symptoms than standard reference ranges, emphasizing the importance of individualized assessment.[46] In pituitary-dependent causes of hyperthyroidism, such as TSH-secreting pituitary adenomas, TSH levels may be normal or elevated despite high T4 and T3 levels. Additionally, an increase in free alpha-subunit concentrations can help confirm the diagnosis of a TSH-secreting adenoma. For Graves disease, the presence of thyroid receptor antibodies (TRAb) is diagnostic, with a sensitivity

Journal of Ecohumanism
2024
Volume: 3, No: 8, pp. 14167 – 14187
ISSN: 2752-6798 (Print) | ISSN 2752-6801 (Online)
https://ecohumanism.co.uk/joe/ecohumanism
DOI: https://doi.org/10.62754/joe.v3i8.6617

of 98% and a specificity of 99%. Thyroid peroxidase antibodies (TPOAb) are also found in approximately 75% of Graves disease cases, although they are less specific.[23]

Imaging Studies

Radioactive iodine uptake (RAIU) studies and thyroid scans are valuable tools for differentiating between the causes of thyrotoxicosis, particularly when Graves' disease is not the obvious diagnosis. In Graves' disease, RAIU typically shows diffuse uptake unless nodules or fibrosis are present. In contrast, a toxic adenoma will demonstrate focal uptake in the adenoma with suppressed uptake in the surrounding thyroid tissue, while toxic multinodular goiter will show multiple areas of increased focal uptake with suppression in the surrounding tissue. In conditions such as painless thyroiditis, postpartum thyroiditis, subacute thyroiditis, or cases of thyroid hormone ingestion, RAIU is typically near zero due to the absence of active hormone production by the thyroid gland.[27] Thyroid ultrasound is another useful imaging modality, particularly for detecting nodules and assessing thyroid morphology. While both ultrasound and RAIU are equally sensitive for diagnosing Graves' disease, ultrasound offers several advantages, including the absence of radiation exposure, improved nodule detection, and lower cost. Thyroid scintigraphy is recommended when thyroid nodules are present or when the etiology of thyrotoxicosis is unclear.[4] In subacute thyroiditis, inflammatory markers such as erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP) are frequently elevated. A T3:T4 ratio of less than 20 also suggests thyroiditis, as it reflects the ratio of stored thyroid hormones released during follicular destruction.[4]

Special Considerations in Pregnancy

During pregnancy, the evaluation of thyrotoxicosis requires careful interpretation of thyroid function tests due to physiological changes in thyroid hormone levels. Gestational transient thyrotoxicosis is characterized by suppressed TSH and elevated T4 levels in early pregnancy, driven by high serum human chorionic gonadotropin (hCG) levels, which have TSH-like activity. The diagnosis should include serum TSH levels along with either free T3 (fT3) and fT4 or total T3 and T4, using an adjusted reference range 1.5 times the nonpregnant range. In the first half of pregnancy, serum TSH levels may be lower than the nonpregnant reference range, but fT4 values should remain normal.[2][8][49]

Thyroid Storm

Thyroid storm, a life-threatening complication of thyrotoxicosis, is diagnosed based on clinical symptoms and laboratory findings. Key diagnostic features include low or undetectable TSH levels (<0.01 mU/L), elevated fT4 and fT3 levels, and, in some cases, positive thyroid receptor antibodies. Given the high mortality rate of thyroid storm, clinicians should maintain a high index of suspicion in patients presenting with classic symptoms such as tachycardia, fever, altered mental status, and signs of cardiac failure.[50]

Factitious Thyrotoxicosis

Factitious thyrotoxicosis, caused by the intentional ingestion of thyroid hormone supplements, is characterized by elevated T3 and T4 levels with low TSH. A radioactive iodine uptake scan will show decreased uptake, and thyroglobulin levels will be low, reflecting the exogenous source of thyroid hormones. Additionally, Doppler ultrasound may reveal reduced vascularization of the thyroid gland, further supporting the diagnosis.[22] The evaluation of thyrotoxicosis requires a comprehensive approach that integrates clinical findings, laboratory tests, and imaging studies. Accurate diagnosis is essential for identifying the underlying cause and guiding appropriate treatment. Special considerations, such as pregnancy or the presence of thyroid storm, necessitate tailored diagnostic strategies to ensure optimal patient outcomes. Early and accurate diagnosis can prevent complications and improve the prognosis for patients with thyrotoxicosis.

Treatment and Management of Thyrotoxicosis

Journal of Ecohumanism
2024
Volume: 3, No: 8, pp. 14167 – 14187
ISSN: 2752-6798 (Print) | ISSN 2752-6801 (Online)
https://ecohumanism.co.uk/joe/ecohumanism
DOI: https://doi.org/10.62754/joe.v3i8.6617

The management of thyrotoxicosis is tailored to the underlying cause, severity of symptoms, and patient-specific factors such as age, comorbidities, and pregnancy status. Treatment strategies aim to alleviate symptoms, normalize thyroid hormone levels, and address the root cause of the condition. The primary treatment modalities include beta-blockers, thionamide drugs, radioiodine therapy, and thyroid surgery. Each approach has distinct indications, benefits, and risks, which must be carefully considered to optimize patient outcomes.

Beta-Blockers

Beta-blockers, such as propranolol, are commonly used to manage the adrenergic symptoms of thyrotoxicosis, including tachycardia, anxiety, and sweating. Propranolol is particularly effective because it blocks both β1- and β2-adrenergic receptors, providing rapid relief of symptoms. Additionally, propranolol may inhibit the peripheral conversion of thyroxine (T4) to the more active triiodothyronine (T3) by blocking the enzyme 5'-monodeiodinase. However, beta-blockers should be used with caution in patients with asthma due to the risk of bronchospasm.[11]

Thionamide Drugs

Thionamide drugs, including propylthiouracil (PTU) and methimazole, are first-line treatments for hyperthyroidism caused by Graves' disease and other forms of thyrotoxicosis. These medications work by inhibiting thyroid peroxidase, an enzyme essential for the synthesis of thyroid hormones. At higher doses, PTU also blocks the peripheral conversion of T4 to T3, providing an additional therapeutic effect. Methimazole is typically administered at a dose of 15 to 30 mg daily for 4 to 8 weeks, after which most patients achieve a euthyroid state. Once euthyroidism is established, treatment can proceed using one of two approaches: the block-replace method or dose titration. In the block-replace method, the same dose of thionamide is maintained to suppress thyroid hormone production, while levothyroxine is added to maintain normal thyroid function. Alternatively, the thionamide dose can be gradually reduced to allow endogenous hormone synthesis. Methimazole is preferred over PTU due to its longer half-life, allowing for once-daily dosing, and its lower risk of hepatotoxicity. However, both drugs carry a risk of agranulocytosis, which occurs in approximately 1 in 300 patients and presents with symptoms such as sore throat, mouth ulcers, and fever. Minor side effects include pruritus, arthralgia, and gastrointestinal upset.[23] Long-term remission is achieved in about 50% of patients with Graves' disease treated with thionamides. However, the risk of relapse after discontinuation remains a significant drawback. Prolonged treatment beyond 18 months has not been shown to improve remission rates. For patients who continue to exhibit signs of hyperthyroidism or have persistent anti-TSH receptor antibodies after 18 months of treatment, alternative therapies such as radioiodine therapy or surgery should be considered.[23]

Teprotumumab for Graves Orbitopathy

Recent advances in the treatment of Graves orbitopathy include the use of teprotumumab, an insulin-like growth factor-1 receptor (IGF1R) blocker. Increased expression of IGF1R has been observed in the orbital fibroblasts and immune cells of patients with Graves' disease, making it a potential therapeutic target. Teprotumumab, approved by the FDA, has shown promise in reducing the severity of Graves orbitopathy and may also have applications in treating other forms of thyrotoxicosis.[23][41][51]

Radioiodine Therapy

Radioiodine therapy is the most common treatment for Graves' disease in adults in the United States and is also effective for toxic adenomas and toxic multinodular goiter. This therapy involves the oral administration of a single dose of radioactive iodine (I-131), which is selectively absorbed by the thyroid gland. Radiation causes inflammation and fibrosis, leading to the gradual destruction of thyroid tissue over several months. Most patients develop hypothyroidism within 6 to 12 months and require lifelong levothyroxine

Replacement therapy.

Journal of Ecohumanism
2024
Volume: 3, No: 8, pp. 14167 – 14187
ISSN: 2752-6798 (Print) | ISSN 2752-6801 (Online)
https://ecohumanism.co.uk/joe/ecohumanism
DOI: https://doi.org/10.62754/joe.v3i8.6617

Pretreatment with thionamides is recommended for patients with large goiters, severe thyrotoxicosis, or cardiovascular conditions to achieve a euthyroid state before radioiodine therapy. However, radioiodine therapy is contraindicated during pregnancy and lactation, and conception should be avoided for 6 to 12 months post-treatment. A small risk of exacerbation of thyrotoxicosis exists in the first month after treatment due to the release of performed thyroid hormones. Additionally, radioiodine therapy is a known risk factor for the development or worsening of Graves orbitopathy.[23][41][52] For more detailed information, refer to StatPearls' companion resource, "Radioactive Iodine Therapy."

Treatment of Thyroiditis

The management of thyroiditis differs from other forms of thyrotoxicosis because antithyroid drugs are ineffective, as thyroid hormone production is typically reduced. Thyroiditis is usually self-limiting, and treatment focuses on symptom control. Beta-blockers are recommended for patients with symptomatic thyrotoxicosis, particularly those with a resting heart rate exceeding 90 bpm or underlying cardiovascular disease. In cases of subacute thyroiditis, nonsteroidal anti-inflammatory drugs (NSAIDs) or systemic glucocorticoids may be prescribed to manage pain and inflammation.[23]

Management in Children

Children with thyrotoxicosis may be treated with methimazole, radioiodine therapy, or thyroidectomy. Methimazole is the first-line therapy for Graves' disease in children, typically administered for 1 to 2 years, as some children may achieve remission. Radioiodine therapy is generally not recommended for children aged 5 or younger, and PTU should be avoided due to its risk of hepatotoxicity.[23]

Management During Pregnancy

During pregnancy, radioiodine therapy is contraindicated, and treatment options are limited to thionamide drugs or thyroidectomy in severe cases. PTU is preferred during the first trimester due to the teratogenic risks associated with methimazole, such as aplasia cutis and choanal or esophageal atresia. Maternal TSH receptor antibodies can be measured to assess the risk of fetal hyperthyroidism. Gestational transient thyrotoxicosis, caused by elevated hCG levels, typically resolves by 10 to 12 weeks of gestation and does not require antithyroid drugs. Treatment focuses on supportive care for symptoms such as nausea and vomiting.[2][47][52][53] For more information, refer to StatPearls' companion resource, "Hyperthyroidism in Pregnancy."

Thyroid Surgery

Thyroidectomy, whether total or partial, provides rapid and definitive treatment for thyrotoxicosis. However, it is invasive, expensive, and results in permanent hypothyroidism, necessitating lifelong levothyroxine therapy. Pretreatment with thionamides is recommended to achieve an euthyroid state before surgery, reducing the risk of thyroid storm. Surgery is indicated for patients with hyperthyroidism resistant to medical therapy, significant thyroid enlargement causing compressive symptoms, or suspected thyroid cancer. Common complications include transient hypocalcemia due to hypoparathyroidism and vocal cord paresis caused by injury to the recurrent laryngeal nerve.[23] For more detailed information, refer to StatPearls' companion resource, "Thyroidectomy." The treatment of thyrotoxicosis requires a personalized approach based on the underlying cause, severity of symptoms, and patient-specific factors. Beta-blockers provide rapid relief of adrenergic symptoms, while thionamide drugs, radioiodine therapy, and thyroid surgery address the root cause of hyperthyroidism. Special considerations are necessary for children, pregnant women, and patients with thyroiditis or Graves orbitopathy. Early and appropriate management can prevent complications and improve long-term outcomes for patients with thyrotoxicosis.

Differential Diagnosis

Journal of Ecohumanism
2024
Volume: 3, No: 8, pp. 14167 – 14187
ISSN: 2752-6798 (Print) | ISSN 2752-6801 (Online)
https://ecohumanism.co.uk/joe/ecohumanism
DOI: https://doi.org/10.62754/joe.v3i8.6617

Thyrotoxicosis is typically diagnosed through laboratory testing, but several conditions can mimic its clinical presentation. Disorders that stimulate the sympathetic nervous system, such as pheochromocytoma or drug ingestions (e.g., beta-agonists, excessive caffeine, illicit drugs, or supplements), can present with symptoms like tachycardia, sweating, and anxiety, resembling thyrotoxicosis. Primary cardiac conditions, including atrial fibrillation and congestive heart failure, may also mimic thyrotoxicosis due to overlapping symptoms such as palpitations and dyspnea. Hypoglycemia can cause palpitations, tremors, and sweating, while diabetes may present weight loss and fatigue, like thyrotoxicosis. Cushing syndrome can lead to proximal muscle weakness and hypertension, which may be confusing with thyrotoxicosis. Additionally, underlying malignancies can cause weight loss and fatigue, further complicating the differential diagnosis. A thorough clinical evaluation and appropriate diagnostic testing are essential to distinguish thyrotoxicosis from these conditions.[4][11]

Surgical Oncology

The British Association of Endocrine and Thyroid Surgeons (BAETS) supports several key trials aimed at improving the management of thyroid disorders. One study in the United Kingdom compares hemithyroidectomy and total thyroidectomy for low-risk thyroid cancer, focusing on cost-effectiveness and recurrence rates. The RABBIT Trial investigates the use of radiofrequency ablation (RFA) versus open surgery for benign thyroid nodules, involving surgeons and endocrinologists across the UK. The CoNCent Study evaluates the benefits of central neck dissection with completion thyroidectomy for incidental N1a thyroid cancer discovered during hemithyroidectomy. The Thy3000 Study is a national observational study examining the epidemiology and management of thyroid nodules in the UK. Lastly, the NIFTy Trial explores the use of near-infrared fluorescent imaging in thyroid surgery to reduce postsurgical hyperparathyroidism. These trials aim to advance surgical techniques and improve patient outcomes in thyroid disease management.[55]

Pertinent Studies and Ongoing Trials

The Mayo Clinic is conducting several trials related to thyroid disorders, including thyrotoxicosis. These studies focus on various aspects of thyroid disease, such as the use of teprotumumab for thyroid eye disease, the evaluation of different treatment approaches for hyperthyroidism, and the investigation of immune checkpoint inhibitor-related thyroid disease. Additionally, research is underway to develop new clinical tools to support shared decision-making in thyroid disease management. Emerging therapeutics include biologics, small molecule peptides, immunomodulators, and antibodies targeting IGF1R, which show promise in treating Graves' disease and other forms of thyrotoxicosis.[41] Traditional Chinese medicine has also been studied for treating thyrotoxicosis, particularly Graves' disease. Diosgenin, found in fenugreek, has been shown to decrease thyroid proliferation in mice. Resveratrol, produced by injured plants, helps reduce oxidative stress. Icariin, derived from the plant Epimedium brevicornum, has demonstrated a reduction in Graves orbitopathy in mouse models. Several other plant-derived molecules used in traditional Chinese medicine have also shown effectiveness in animal models, offering potential alternative therapies for thyrotoxicosis.[41][54]

Prognosis

The prognosis of thyrotoxicosis depends largely on its underlying cause. Thyroiditis is typically self-limiting and resolves within a few weeks without long-term complications. Graves disease often improves over time, although some patients may experience relapses or require long-term management. In contrast, follicular adenomas and pituitary adenomas generally require definitive treatment, as they can worsen without intervention. Early diagnosis and appropriate treatment are crucial for improving outcomes and preventing complications such as thyroid storm or cardiovascular dysfunction.[4][11]

Complications

Journal of Ecohumanism
2024
Volume: 3, No: 8, pp. 14167 – 14187
ISSN: 2752-6798 (Print) | ISSN 2752-6801 (Online)
https://ecohumanism.co.uk/joe/ecohumanism
DOI: https://doi.org/10.62754/joe.v3i8.6617

Untreated or undiagnosed thyrotoxicosis can progress to thyroid storm, a life-threatening condition characterized by tachycardia, fever, altered mental status, agitation, signs of cardiac failure, and impaired liver function. A thorough history is essential to identify precipitating factors such as major stress, illness, or recent injury. Treatment involves the administration of thionamides, such as methimazole or PTU, to inhibit the synthesis of new thyroid hormones, along with iodine to block the release of preformed hormones. Supportive care, including beta-blockers (preferably propranolol) and fluid resuscitation, is commonly provided in a critical care setting to stabilize the patient and prevent further complications.[4][11]

Patient Education

Patients with thyrotoxicosis should be educated about their condition, including the importance of adhering to prescribed medications and attending routine follow-up appointments to monitor for disease progression. Patient education should also emphasize recognizing symptoms of complications, such as thyroid storm, and seeking prompt medical attention if they occur. Lifestyle modifications, such as avoiding excessive iodine intake and managing stress, can also help prevent exacerbations of thyrotoxicosis. Providing patients with clear, accessible information and involving them in their treatment decisions can improve adherence and outcomes.[4][11]

Enhancing Healthcare Team Outcomes

The management of thyrotoxicosis often requires a collaborative approach involving an interdisciplinary healthcare team. In stable cases, treatment can be managed in an outpatient setting by a primary care physician or endocrinologist. However, acute conditions such as thyroid storm necessitate hospitalization and close monitoring in an intensive care unit. The healthcare team should include critical care physicians, primary care providers, endocrinologists, radiologists, surgeons, advanced practitioners, nurses, physical therapists, and pharmacists. Each team member plays a crucial role in providing patient-centered care, from diagnosis and treatment to patient education and follow-up. Open communication and care coordination, often facilitated by a nurse navigator, ensure timely interventions and patient safety. Emphasizing a patient-centered approach, where patients are actively involved in their treatment decisions, enhances adherence and leads to improved health outcomes.[4][11]

Role of Anesthesiologists, Pharmacists, and Other Healthcare Professionals in Thyrotoxicosis

Thyrotoxicosis is a complex condition that requires a multidisciplinary approach for effective management. Anesthesiologists, pharmacists, and other healthcare professionals play critical roles in the diagnosis, treatment, and ongoing care of patients with thyrotoxicosis. Their expertise ensures safe and effective management, particularly in acute settings such as thyroid storm or during surgical interventions.

Role of Anesthesiologists

Anesthesiologists are essential in managing patients with thyrotoxicosis, particularly during surgical procedures such as thyroidectomy or in cases of thyroid storm requiring intensive care. Their responsibilities include:

- Preoperative Assessment: Anesthesiologists evaluate patients with thyrotoxicosis to assess the severity of their condition and identify any associated complications, such as cardiovascular instability or airway compromise due to a large goiter. They ensure that patients are euthyroid before surgery to minimize the risk of perioperative complications, including thyroid storm.

- Intraoperative Management: During thyroidectomy or other surgeries, anesthesiologists monitor and manage the patient's hemodynamic stability, as thyrotoxicosis can exacerbate cardiovascular responses to anesthesia. They administer medications to control heart rate and blood pressure, such as beta-blockers, and ensure adequate pain control and sedation.

Journal of Ecohumanism
2024
Volume: 3, No: 8, pp. 14167 – 14187
ISSN: 2752-6798 (Print) | ISSN 2752-6801 (Online)
https://ecohumanism.co.uk/joe/ecohumanism
DOI: https://doi.org/10.62754/joe.v3i8.6617

- Management of Thyroid Storm: In cases of thyroid storm, anesthesiologists play a vital role in stabilizing critically ill patients in the intensive care unit (ICU). They manage airway and ventilation, administer intravenous fluids, and provide supportive care while coordinating with endocrinologists to initiate definitive treatment.

- Postoperative Care: Anesthesiologists monitor patients postoperatively for complications such as hypocalcemia (due to accidental parathyroid gland removal) or recurrent laryngeal nerve injury, which can affect breathing and vocal function. They also ensure adequate pain management and recovery from anesthesia.

Role of Pharmacists

Pharmacists are integral to the management of thyrotoxicosis, particularly in optimizing medication regimens and ensuring patient safety. Their roles include:

- Medication Management: Pharmacists ensure that patients receive appropriate doses of antithyroid medications, such as methimazole or propylthiouracil (PTU), and monitor for potential side effects, including hepatotoxicity and agranulocytosis. They also advise on the use of beta-blockers for symptom control and educate patients on proper medication adherence.

- Monitoring Drug Interactions: Pharmacists identify and manage potential drug interactions, particularly in patients taking multiple medications. For example, they ensure that iodine-containing drugs, such as amiodarone, are used cautiously in patients with thyrotoxicosis.

- Patient Education: Pharmacists educate patients about their medications, including the importance of taking them as prescribed and recognizing signs of adverse effects. They also provide guidance on lifestyle modifications, such as avoiding excessive iodine intake.

- Support in Thyroid Storm: In acute settings, pharmacists assist in preparing and administering medications such as intravenous beta-blockers, corticosteroids, and iodine solutions. They ensure that medications are administered safely and monitor for potential complications.

Role of Other Healthcare Professionals

- Endocrinologists: Endocrinologists lead the diagnosis and management of thyrotoxicosis, determining the underlying cause and initiating appropriate treatment. They monitor thyroid function tests and adjust treatment regimens as needed.

- Primary Care Physicians: Primary care providers often identify early symptoms of thyrotoxicosis and refer patients to endocrinologists for further evaluation. They also play a role in long-term follow-up and monitoring.

- Nurses: Nurses provide critical support in both inpatient and outpatient settings. They monitor patients for symptoms, administer medications, and educate patients about their condition and treatment. In acute settings, such as thyroid storm, nurses ensure close monitoring of vital signs and provide supportive care.

- Surgeons: Surgeons perform thyroidectomy in cases where medical management is insufficient or contraindicated. They work closely with anesthesiologists and endocrinologists to ensure safe and effective surgical outcomes.

- Dietitians: Dietitians provide guidance on nutrition, particularly in patients with weight loss or those requiring dietary modifications to support thyroid health.

Journal of Ecohumanism
2024
Volume: 3, No: 8, pp. 14167 – 14187
ISSN: 2752-6798 (Print) | ISSN 2752-6801 (Online)
https://ecohumanism.co.uk/joe/ecohumanism
DOI: https://doi.org/10.62754/joe.v3i8.6617

- Mental Health Professionals: Given the psychiatric manifestations of thyrotoxicosis, such as anxiety and depression, mental health professionals may be involved in providing counseling and support.

Collaborative Approach

Effective management of thyrotoxicosis requires collaboration among all healthcare professionals. Regular communication, shared decision-making, and a patient-centered approach ensure that patients receive comprehensive care. For example, in thyroid storm, the rapid coordination between endocrinologists, anesthesiologists, pharmacists, and nurses is critical to stabilizing the patient and preventing mortality. In conclusion, anesthesiologists, pharmacists, and other healthcare professionals play vital roles in the management of thyrotoxicosis. Their expertise ensures safe and effective treatment, particularly in acute and complex cases. A collaborative, multidisciplinary approach is essential for optimizing patient outcomes and improving quality of life for individuals with thyrotoxicosis.

Conclusion

Thyrotoxicosis is a complex clinical syndrome with diverse etiologies and manifestations, requiring a comprehensive understanding of its pathophysiology, diagnosis, and management. Graves' disease remains the most common cause, followed by toxic multinodular goiter and thyroiditis. The condition's systemic effects, particularly on the cardiovascular, nervous, and musculoskeletal systems, underscore the importance of timely diagnosis and intervention. Laboratory testing, including suppressed TSH and elevated T3/T4 levels, forms the cornerstone of diagnosis, while imaging studies such as radioactive iodine uptake and thyroid ultrasound help identify the underlying cause. Treatment strategies for thyrotoxicosis are tailored to the underlying etiology and patient-specific factors. Beta-blockers, such as propranolol, provide rapid relief of adrenergic symptoms, while thionamide drugs like methimazole and propylthiouracil (PTU) inhibit thyroid hormone synthesis. Radioiodine therapy is a definitive treatment for Graves' disease and toxic nodules, though it carries a risk of hypothyroidism and exacerbation of Graves' orbitopathy. Thyroidectomy is reserved for cases resistant to medical therapy or with compressive symptoms. Emerging therapies, such as teprotumumab, an IGF1R blocker, offer new hope for managing Graves' orbitopathy and other forms of thyrotoxicosis. Special considerations are necessary for specific populations, including pregnant women and children. During pregnancy, PTU is preferred in the first trimester due to its lower teratogenic risk, while radioiodine therapy is contraindicated. In children, methimazole is the first-line treatment, with radioiodine therapy generally avoided in those under five years of age. Thyroiditis, often self-limiting, requires supportive care with beta-blockers and anti-inflammatory medications. The prognosis of thyrotoxicosis varies depending on the underlying cause. While thyroiditis typically resolves spontaneously, Graves' disease may require long-term management, and toxic adenomas often necessitate definitive treatment. Complications such as thyroid storm, though rare, are life-threatening and require urgent intervention. In conclusion, thyrotoxicosis is a multifaceted condition that demands a personalized approach to diagnosis and treatment. Advances in therapeutic options, including biologics and targeted therapies, hold promise for improving patient outcomes. A collaborative, interdisciplinary approach involving endocrinologists, primary care providers, surgeons, and other healthcare professionals is essential for optimizing care and ensuring favorable long-term outcomes for patients with thyrotoxicosis.

References

Ross DS, Burch HB, Cooper DS, Greenlee MC, Laurberg P, Maia AL, Rivkees SA, Samuels M, Sosa JA, Stan MN, Walter MA. 2016 American Thyroid Association Guidelines for Diagnosis and Management of Hyperthyroidism and Other Causes of Thyrotoxicosis. Thyroid. 2016 Oct;26(10):1343-1421.

Devereaux D, Tewelde SZ. Hyperthyroidism and thyrotoxicosis. Emerg Med Clin North Am. 2014 May;32(2):277-92.

Biondi B, Cooper DS. The clinical significance of subclinical thyroid dysfunction. Endocr Rev. 2008 Feb;29(1):76-131.

Lee SY, Pearce EN. Hyperthyroidism: A Review. JAMA. 2023 Oct 17;330(15):1472-1483.

Shin K, Kim J, Park J, Oh TJ, Kong SH, Ahn CH, Moon JH, Kim MJ, Moon JH. A machine learning-assisted system to predict thyrotoxicosis using patients' heart rate monitoring data: a retrospective cohort study. Sci Rep. 2023 Nov 30;13(1):21096.

Journal of Ecohumanism
2024
Volume: 3, No: 8, pp. 14167 – 14187
ISSN: 2752-6798 (Print) | ISSN 2752-6801 (Online)
https://ecohumanism.co.uk/joe/ecohumanism
DOI: https://doi.org/10.62754/joe.v3i8.6617

Adams R, Oh ES, Yasar S, Lyketsos CG, Mammen JS. Endogenous and Exogenous Thyrotoxicosis and Risk of Incident Cognitive Disorders in Older Adults. JAMA Intern Med. 2023 Dec 01;183(12):1324-1331.
Smith TJ, Hegedüs L. Graves' Disease. N Engl J Med. 2016 Oct 20;375(16):1552-1565.
Sharma A, Stan MN. Thyrotoxicosis: Diagnosis and Management. Mayo Clin Proc. 2019 Jun;94(6):1048-1064.
Smith TJ, Hegedüs L. Graves' Disease. N Engl J Med. 2017 Jan 12;376(2):185.
Kravets I. Hyperthyroidism: Diagnosis and Treatment. Am Fam Physician. 2016 Mar 01;93(5):363-70.
Campennì A, Avram AM, Verburg FA, Iakovou I, Hänscheid H, de Keizer B, Petranović Ovčariček P, Giovanella L. The EANM guideline on radioiodine therapy of benign thyroid disease. Eur J Nucl Med Mol Imaging. 2023 Sep;50(11):3324-3348.
Razvi S, Bhana S, Mrabeti S. Challenges in Interpreting Thyroid Stimulating Hormone Results in the Diagnosis of Thyroid Dysfunction. J Thyroid Res. 2019;2019:4106816.
Jung CK, Bychkov A, Kakudo K. Update from the 2022 World Health Organization Classification of Thyroid Tumors: A Standardized Diagnostic Approach. Endocrinol Metab (Seoul). 2022 Oct;37(5):703-718.
Beck-Peccoz P, Giavoli C, Lania A. A 2019 update on TSH-secreting pituitary adenomas. J Endocrinol Invest. 2019 Dec;42(12):1401-1406.
Beck-Peccoz P, Persani L, Lania A. Thyrotropin-Secreting Pituitary Adenomas. In: Feingold KR, Anawalt B, Blackman MR, Boyce A, Chrousos G, Corpas E, de Herder WW, Dhatariya K, Dungan K, Hofland J, Kalra S, Kaltsas G, Kapoor N, Koch C, Kopp P, Korbonits M, Kovacs CS, Kuohung W, Laferrère B, Levy M, McGee EA, McLachlan R, New M, Purnell J, Sahay R, Shah AS, Singer F, Sperling MA, Stratakis CA, Trence DL, Wilson DP, editors. Endotext [Internet]. MDText.com, Inc.; South Dartmouth (MA): Oct 13, 2022.
Chivukula KK, Toro-Tobón D, Motazedi B, Goyal R. Thyroid storm as an early presentation of hCG-producing metastatic choriocarcinoma: a case report and review of the literature. BMJ Case Rep. 2021 Sep 27;14(9)
Anfinsen OG, Lima K. Amiodarone-induced thyrotoxicosis. Tidsskr Nor Laegeforen. 2021 Nov 09;141(16)
Bahn RS, Burch HB, Cooper DS, Garber JR, Greenlee MC, Klein I, Laurberg P, McDougall IR, Montori VM, Rivkees SA, Ross DS, Sosa JA, Stan MN., American Thyroid Association. American Association of Clinical Endocrinologists. Hyperthyroidism and other causes of thyrotoxicosis: management guidelines of the American Thyroid Association and American Association of Clinical Endocrinologists. Endocr Pract. 2011 May-Jun;17(3):456-520.
Tondi Resta I, Sande CM, LiVolsi VA. Neoplasms in Struma Ovarii: A Review. Endocr Pathol. 2023 Dec;34(4):455-460.
Pattarawongpaiboon C, Srisawat N, Tungsanga K, Champunot R, Somboonjun J, Srichomkwun P. Clinical characteristics and outcomes of an exogenous thyrotoxicosis epidemic in prison. BMJ Nutr Prev Health. 2023;6(2):318-325.
Topliss DJ, Soh SB. Use and misuse of thyroid hormone. Singapore Med J. 2013 Jul;54(7):406-10.
Persani L, dell'Acqua M, Ioakim S, Campi I. Factitious thyrotoxicosis and thyroid hormone misuse or abuse. Ann Endocrinol (Paris). 2023 May;84(3):367-369.
Kahaly GJ. Management of Graves Thyroidal and Extrathyroidal Disease: An Update. J Clin Endocrinol Metab. 2020 Dec 01;105(12):3704-20.
Roman BR, Feingold JH, Patel SG, Shaha AR, Shah JP, Tuttle RM, Epstein AJ. The 2009 American Thyroid Association guidelines modestly reduced radioactive iodine use for thyroid cancers less than 1 cm. Thyroid. 2014 Oct;24(10):1549-50.
Woo T, Li C, Ganesananthan S, Rajendram R, Uddin J, Lee RWJ, Dayan C, Taylor P. The Effect of Ophthalmic Surgery for Graves' Orbitopathy on Quality of Life: A Systematic Review and Meta-Analysis. Thyroid. 2022 Feb;32(2):177-187.
Martinez Quintero B, Yazbeck C, Sweeney LB. Thyroiditis: Evaluation and Treatment. Am Fam Physician. 2021 Dec 01;104(6):609-617.
De Leo S, Lee SY, Braverman LE. Hyperthyroidism. Lancet. 2016 Aug 27;388(10047):906-918.
Vacante M, Biondi A, Basile F, Ciuni R, Luca S, Di Saverio S, Buscemi C, Vicari ESD, Borzì AM. Hypothyroidism as a Predictor of Surgical Outcomes in the Elderly. Front Endocrinol (Lausanne). 2019;10:258.
Moleti M, Di Mauro M, Sturniolo G, Russo M, Vermiglio F. Hyperthyroidism in the pregnant woman: Maternal and fetal aspects. J Clin Transl Endocrinol. 2019 Jun;16:100190.
Bianco AC, Dumitrescu A, Gereben B, Ribeiro MO, Fonseca TL, Fernandes GW, Bocco BMLC. Paradigms of Dynamic Control of Thyroid Hormone Signaling. Endocr Rev. 2019 Aug 01;40(4):1000-1047.
McAninch EA, Bianco AC. Thyroid hormone signaling in energy homeostasis and energy metabolism. Ann N Y Acad Sci. 2014 Apr;1311:77-87.
Salvatore D, Simonides WS, Dentice M, Zavacki AM, Larsen PR. Thyroid hormones and skeletal muscle--new insights and potential implications. Nat Rev Endocrinol. 2014 Apr;10(4):206-14.
Bloise FF, Oliveira TS, Cordeiro A, Ortiga-Carvalho TM. Thyroid Hormones Play Role in Sarcopenia and Myopathies. Front Physiol. 2018;9:560.
Kim SM, Ryu V, Miyashita S, Korkmaz F, Lizneva D, Gera S, Latif R, Davies TF, Iqbal J, Yuen T, Zaidi M. Thyrotropin, Hyperthyroidism, and Bone Mass. J Clin Endocrinol Metab. 2021 Nov 19;106(12):e4809-e4821.
Kim, H. Y., & Mohan, S. (2013). Role and mechanisms of actions of thyroid hormone on the skeletal development. Bone research, 1(1), 146-161.
Kim HY, Mohan S. Role and Mechanisms of Actions of Thyroid Hormone on the Skeletal Development. Bone Res. 2013 Jun;1(2):146-61.
Ressler HW, Shah K, Quattlebaum T, Munjal S. Catatonia and Psychosis Associated With Hyperthyroidism. Prim Care Companion CNS Disord. 2023 Nov 23;25(6)
Iskandar M, Stepanova E, Francis A. Two cases of catatonia with thyroid dysfunction. Psychosomatics. 2014 Nov-Dec;55(6):703-7.

Journal of Ecohumanism
2024
Volume: 3, No: 8, pp. 14167 – 14187
ISSN: 2752-6798 (Print) | ISSN 2752-6801 (Online)
https://ecohumanism.co.uk/joe/ecohumanism
DOI: https://doi.org/10.62754/joe.v3i8.6617
Perez-Montiel MD, Suster S. The spectrum of histologic changes in thyroid hyperplasia: a clinicopathologic study of 300 cases. Hum Pathol. 2008 Jul;39(7):1080-7.
Brancatella A, Torregrossa L, Viola N, Sgrò D, Casula M, Basolo F, Materazzi G, Marinò M, Marcocci C, Santini F, Latrofa F. In Graves' disease, thyroid autoantibodies and ultrasound features correlate with distinctive histological features. J Endocrinol Invest. 2023 Aug;46(8):1695-1703.
He Q, Dong H, Gong M, Guo Y, Xia Q, Gong J, Lu F. New Therapeutic Horizon of Graves' Hyperthyroidism: Treatment Regimens Based on Immunology and Ingredients From Traditional Chinese Medicine. Front Pharmacol. 2022;13:862831.
Xie F, Johnson EF, Youssef MJ. Thyroid Dermopathy and Acropachy. Mayo Clin Proc. 2022 Dec;97(12):2314-2315.
Taguchi T. Clinical Imaging Features of Thyroid Acropachy. Intern Med. 2022 Jan 15;61(2):133-134.
Bartalena L, Fatourechi V. Extrathyroidal manifestations of Graves' disease: a 2014 update. J Endocrinol Invest. 2014 Aug;37(8):691-700.
Samuels SL, Namoc SM, Bauer AJ. Neonatal Thyrotoxicosis. Clin Perinatol. 2018 Mar;45(1):31-40.
Andersen S, Karmisholt J, Bruun NH, Riis J, Noahsen P, Westergaard L, Andersen SL. Interpretation of TSH and T4 for diagnosing minor alterations in thyroid function: a comparative analysis of two separate longitudinal cohorts. Thyroid Res. 2022 Oct 10;15(1):19.
Lee SY, Pearce EN. Assessment and treatment of thyroid disorders in pregnancy and the postpartum period. Nat Rev Endocrinol. 2022 Mar;18(3):158-171.
Lee SY, Pearce EN. Testing, Monitoring, and Treatment of Thyroid Dysfunction in Pregnancy. J Clin Endocrinol Metab. 2021 Mar 08;106(3):883-892.
Fu H, Cheng L, Jin Y, Chen L. Thyrotoxicosis with concomitant thyroid cancer. Endocr Relat Cancer. 2019 Jul;26(7):R395-R413.
De Almeida R, McCalmon S, Cabandugama PK. Clinical Review and Update on the Management of Thyroid Storm. Mo Med. 2022 Jul-Aug;119(4):366-371.
Smith TJ, Hegedüs L, Douglas RS. Role of insulin-like growth factor-1 (IGF-1) pathway in the pathogenesis of Graves' orbitopathy. Best Pract Res Clin Endocrinol Metab. 2012 Jun;26(3):291-302.
Kobaly K, Mandel SJ. Hyperthyroidism and Pregnancy. Endocrinol Metab Clin North Am. 2019 Sep;48(3):533-545.
Brito JP, Castaneda-Guarderas A, Gionfriddo MR, Ospina NS, Maraka S, Dean DS, Castro MR, Fatourechi V, Gharib H, Stan MN, Branda ME, Bahn RS, Montori VM. Development and Pilot Testing of an Encounter Tool for Shared Decision Making About the Treatment of Graves' Disease. Thyroid. 2015 Nov;25(11):1191-8.
Li H, Min J, Chen Y, Li H, Zhang Y. Polydatin attenuates orbital oxidative stress in Graves' orbitopathy through the NRF2 pathway. Chem Biol Interact. 2020 Jan 05;315:108894.

Journal of Ecohumanism
2024
Volume: 3, No: 8, pp. 14167 – 14187
ISSN: 2752-6798 (Print) | ISSN 2752-6801 (Online)
https://ecohumanism.co.uk/joe/ecohumanism
DOI: https://doi.org/10.62754/joe.v3i8.6617

التسمم الدرقي: مراجعة محدثة للأطباء والصيادلة وأخصائي التخدير ومقدمي الرعاية الصحية

ملخص:

الخلفية :التسمم الدرقي هو متلازمة سريرية ناتجة عن فرط نشاط هرمونات الغدة الدرقية، وخاصة هرموني ثلاثي يود الثيرونين (T3) والثيروكسين (T4). وهو يختلف عن فرط نشاط الغدة الدرقية، الذي يشير تحديدًا إلى الإفراط في إنتاج هرمونات الغدة الدرقية من قبل الغدة نفسها. يشمل التسمم الدرقي حالات مختلفة، بما في ذلك مرض جريفز، والتهاب الغدة الدرقية، والعقيدات السامة، وتناول الهرمونات الخارجية. إذا لم يتم علاجه، يمكن أن يؤدي إلى مضاعفات خطيرة مثل اختلال وظائف القلب، وهشاشة العظام، والعاصفة الدرقية، وهي حالة طارئة تهدد الحياة. تظهر الحالة بأعراض متنوعة، بما في ذلك فقدان الوزن، وعدم تحمل الحرارة، وخفقان القلب، والقلق، مما يتطلب نهجًا تشخيصيًا دقيقًا.

الهدف :تهدف هذه المراجعة إلى تقديم نظرة عامة محدثة عن التسمم الدرقي، مع التركيز على أسبابه، وعلم الأمراض، والتظاهرات السريرية، والتقييم التشخيصي، واستراتيجيات العلاج. كما تسلط الضوء على أهمية التمييز بين التسمم الدرقي والحالات الأخرى ذات الأعراض المشابهة، وتناقش العلاجات الناشئة والأبحاث الجارية. تركز المراجعة أيضًا على الدور الرئيسي للصيادلة وأخصائي التخدير في إدارة التسمم الدرقي.

المنهجية :تقوم المراجعة بجمع الأدبيات الحالية حول التسمم الدرقي، بما في ذلك علم الأوبئة، وعلم الأمراض، وطرق العلاج. تتضمن الإرشادات السريرية، ومعايير التشخيص، والنهج العلاجية، مدعومة بأدلة من الدراسات والتجارب الحديثة. كما يتم مناقشة الاعتبارات الخاصة للسكان المحددين، مثل النساء الحوامل والأطفال.

النتائج :يحدث التسمم الدرقي في الغالب بسبب مرض جريفز، والتضخم متعدد العقيدات السام، والتهاب الغدة الدرقية. يعتمد التشخيص على انخفاض مستويات هرمون TSH وارتفاع مستوياتT3/T4 ، مع استخدام الدراسات التصويرية للمساعدة في تحديد السبب الكامن. تشمل خيارات العلاج حاصرات بيتا لتخفيف الأعراض، والأدوية الثيوناميدية، والعلاج باليود المشع، واستئصال الغدة الدرقية. تظهر العلاجات الناشئة، مثل تيبروتومومات لعلاج اعتلال العين المرتبط بمرض جريفز، نتائج واعدة. يعد التشخيص المبكر والعلاج المخصص أمرًا بالغ الأهمية لمنع المضاعفات وتحسين النتائج.

الكلمات المفتاحية :التسمم الدرقي، فرط نشاط الغدة الدرقية، مرض جريفز، التهاب الغدة الدرقية، العلاج باليود المشع، العاصفة الدرقية، تيبروتومومات.